NRG1 and neoplasm: The analysis performed by Gupta et al. detected NRG1 fusion occurrence in 0.15% of tumor specimens, and each single tumor type showed a prevalence rate of 0.30% for breast cancer and 0.26% for cholangiocarcinoma along with 0.23% NSCLC, 0.22% carcinoma of unknown primary, 0.19% pancreatic cancer, 0.17% ovarian cancer, 0.15% bladder cancer, 0.15% esophageal cancer, and 0.15% vulvar cancer [40].